FDA knocks back Alkermes’ opioid-based depression therapy over lack of evidence
pharmafile | February 4, 2019 | News story | Sales and Marketing | Alkermes, FDA, major depressive disorder, pharma, rejection
Alkermes experimental opioid-based depression therapy ALKS 5461 has been rejected by the FDA, it has emerged, in the adjunctive treatment of major depressive disorder (MDD).
The US agency confirmed the decision in a complete response letter, refusing to approve the drug in its current form. Alkermes has been requested to provide additional data to support its efficacy, and the company, in turn, confirmed that it would meet with the FDA to discuss how these concerns could be rectified.
The manufacturer did not state whether it would continue development of the therapy, only noting that this decision will be taken in light of its meeting with the FDA.
The FDA’s rejection comes after strong opposition from an agency advisory panel which questioned both the product’s safety and efficacy.
The drug, a once-daily combination of samidorphan and buprenorphine, is aiming to become the first opioid-based treatment approved for MDD, a condition which affects 16.2 million in the US alone, two-thirds of which do not respond to currently available therapies.
Matt Fellows
Related Content
FDA approves ImmunityBio’s Anktiva bladder cancer treatment
ImmunityBio has announced that the US Food and Drug Administration (FDA) has approved Anktiva (N-803, …
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy
Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as …